FDA to Consumers: Don’t Use These Hyaluronic Acid Products

 The FDA has issued an advisory to consumers, urging them not to buy or use an array of products that, on labeling, contain hyaluronic acid but that contain “hidden” ingredients that are not included in the labeling.

The products — including Curcuflex, DINA Acido Hialuronico, KUKA FLEX CBD, Umary, and others — are marketed and sold as joint pain relief treatments online at sites such as ebay.com and possibly in some retail stores, the agency said. But these products can pose risks that the consumer doesn’t even know about, according to the agency.

“Using these products pose a serious risk to your health,” the advisory said. “These products can lead to severe health issues and hospitalization. FDA urges consumers taking these products to immediately talk with their doctor about how to safely stop using the product.” Talking with a doctor is important because sudden discontinuation of some of the products can cause withdrawal symptoms, the FDA cautioned.

Here are the products the FDA is urging the public not to use:

Curcuflex is a product that is promoted and sold for pain relief on eBay and other sites and possibly in some retail stores, the FDA says. An FDA lab analysis confirmed that it contains dexamethasone and diclofenac, which are not listed on the product’s label.

Dexamethasone, a corticosteroid, can impair the body’s ability to fight infections and can cause high blood sugar, muscle injuries, and psychiatric problems.

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that can increase risk for cardiovascular events and serious gastrointestinal damage. Interactions with other drugs, particularly other NSAIDS, also carry risk, the advisory says.

DINA Acido Hialuronico has been found on FDA lab analysis to contain dexamethasone; methocarbamol, a muscle relaxant; meloxicam, an NSAID; and phenolphthalein, an active ingredient not approved for any drug in the US — all not listed on the label.

Methocarbamol can cause sedation, dizziness, and low blood pressure. Meloxicam carries risks similar to diclofenac. And studies have suggested phenolphthalein might increase cancer risk, the FDA said.

KUKA FLEX CBD, promoted for joint pain relief and sold on eBay, has been found in FDA lab analysis to contain diclofenac, which is not on the label.

Umary, sold on ibeautystore.com, contains diclofenac, dexamethasone, and omeprazole, a proton pump inhibitor for stomach acid disorders, according to FDA analysis. Omeprazole can cause skin reactions, abdominal pain, diarrhea, and other symptoms.

RM Joe, also sold for joint pain relief on websites including naturistamexicanstore.com, has been found on analysis to contain dexamethasone phosphate and diclofenac, which are not on the label, the FDA said.

Yeicob Ácido Hialurónico, sold on websites including raysvitamins.com, contains dexamethasone phosphate and diclofenac that are not on the product label, according to its analysis, the FDA said.

Flexi Bion, sold on websites including eBay, was found on analysis to contain dexamethasone and diclofenac, the advisory said.

Dolotrex, sold on websites including www.innovacionnatural.com, was found on analysis to contain diclofenac, which is not on its label, according to the FDA.

https://www.medscape.com/viewarticle/fda-consumers-dont-use-these-hyaluronic-acid-products-2026a1000aya

'No Clinical Benefit of Antiamyloids in Alzheimer’s Review Concludes'

 Antiamyloid monoclonal antibodies provide no clinically meaningful benefit for patients with mild cognitive impairment (MCI) or early Alzheimer’s disease (AD), results of a large systematic review showed. However, some experts argue the analysis is skewed because it included failed drug trials in its pooled analysis.

Across 17 randomized controlled phase 3 trials involving more than 20,000 participants and covering seven antiamyloid therapies, treatment effects on cognition, dementia severity, and functional ability were consistently small and fell below established thresholds for clinical importance.

The drugs were also associated with a substantially increased risk for amyloid-related imaging abnormalities (ARIA), particularly ARIA-E (edema).

“Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients,” investigator Francesco Nonino, MD, neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna in Bologna, Italy, said in a news release.

“There is now a convincing body of evidence converging on the conclusion that there is no clinically meaningful effect,” he added.

The review’s broad class-level conclusion quickly drew pushback from outside experts who noted that only two of the drugs in the review — lecanemab and donanemab — had positive phase 3 data and current clinical use. The remaining five drugs failed to meet their respective study outcomes.

“This review does not clarify the evidence, it blurs it,” Bart De Strooper, MD, PhD, group leader at the UK Dementia Research Institute at University College London in London, England, said in a statement from the UK nonprofit Science Media Centre. Pooling failed first-generation antibodies with lecanemab and donanemab turns therapeutic progress into “statistical noise,” he added.

David Knopman, MD, professor of neurology at the Mayo Clinic in Rochester, Minnesota, raised a similar concern, adding that the analysis does not resolve the still-open question of whether the newer agents deliver clinically meaningful benefit in practice.

The study was published online on April 16 in the Cochrane Database of Systematic Reviews.

Assessing Clinical Benefit

The amyloid cascade hypothesis has long guided AD drug development, leading to the development of agents designed to clear amyloid-beta early in the disease course in hopes of slowing clinical decline.

The FDA has approved three such drugs: aducanumab in 2021, lecanemab in 2023, and donanemab a year later. But manufacturer Biogen pulled aducanumab from the market in early 2024, a decision the company attributed to efforts to “reprioritize its resources” toward other AD agents.

That marked the end of a rocky road for aducanumab, whose approval was met with criticism from an FDA advisory panel that had recommended the agency reject the drug due to insufficient evidence of clinical efficacy. Three members of the panel — including Knopman — resigned in protest following the decision.

Lecanemab and donanemab had a smoother path to market, with both receiving unanimous recommendations for approval from the FDA expert panel.

However, the question of whether amyloid removal translates into meaningful clinical benefits persists.

To examine this further, investigators conducted a systematic review and meta-analysis of 17 placebo-controlled phase 3 trials covering seven antiamyloid monoclonal antibodies.

The trials were conducted between 2014 and 2024 and included 20,342 participants (mean age, 69.5-73.9 years) with MCI or mild dementia due to AD. About two thirds of patients were women, and most were White. Disease duration ranged from 17 to 52 months and follow-up from 18 to 27 months.

Drugs included donanemab, lecanemab, aducanumab, bapineuzumab, crenezumab, gantenerumab, and solanezumab. Pooled data combined results on the two approved drugs and older agents. All studies compared active treatment with placebo.

Primary outcomes included cognitive function, dementia severity, and functional ability, which were assessed using validated scales such as the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog; range 0-70), Clinical Dementia Rating Scale Sum of Boxes (CDR-SB; range 0-18), and Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL and variants).

Limited Clinical Effects

At 18 months, pooled effects on cognitive outcomes were consistently small across studies. The absolute difference favoring treatment was approximately 0.85 points on the ADAS-Cog compared with minimal clinically important differences of 2-4 points depending on disease stage.

Dementia severity showed similarly small effects, with a pooled difference of 0.29 points on the CDR-SB, well below the threshold considered clinically meaningful.

Across ADCS-ADL and related scales, standardized mean differences were trivial, the researchers noted, with absolute differences ranging from approximately 0.07 to 1.90.

At 24 months and beyond, results remained consistent, with no evidence of clinically meaningful improvement. No clinically meaningful differences were observed in behavioral symptoms.

While efficacy findings were modest, safety signals were more pronounced. Risk for any ARIA-E was approximately 10-fold higher in the treatment group at 18 months (relative risk [RR], 10.02; 95% CI, 7.49-13.41) and at 24 months (RR, 7.49). Symptomatic ARIA-E was less frequent but still increased compared with placebo, though most events were asymptomatic.

ARIA-H showed variability across trials, with a small increase in risk at later timepoints (RR, 1.86 beyond 24 months). Reporting of symptomatic ARIA was inconsistent, which limited certainty about clinical impact.

Rates of serious adverse events and mortality were similar between groups at all timepoints.

Findings Spark Controversy

The analysis has sparked debate among AD experts, particularly around whether the trials of older failed agents should be pooled with newer, more successful therapies.

The researchers argued that pooling results across therapies tests whether amyloid removal is an effective strategy. However, some experts say this approach may obscure meaningful differences.

Knopman, who was not part of the study, criticized the decision to combine older failed therapies with newer agents that have shown positive results and De Strooper agreed.

“In the review itself, the authors acknowledge that while several first-generation antibodies failed, newer antibodies have produced positive clinical effects, yet they still pool them together and treat the resulting average as if it were an informative judgment on the entire field,” he said.

“The public is left with the impression that antiamyloid therapy has broadly failed and that the field should move on. A serious review should help readers understand that complexity. This one risks obscuring it,” he added.

Knopman also noted that the review does not address regulatory decision-making because several included therapies were never submitted for approval.

More broadly, he said that ARIA risks appear manageable and that the true clinical value of lecanemab and donanemab are still being evaluated in clinical practice.

“I do not dispute the fact that the effect sizes for lecanemab and donanemab are small, but there are no established guidelines as to what constitutes a meaningful change in the Alzheimer field that has no external standard of benefit size to compare to,” Knopman said.

In the end, he said, the review does not address the question of clinical meaningfulness of the two agents that are currently being used.

“Whether lecanemab and donanemab produce clinically meaningful benefits is a matter of debate that will take several years to clarify,” he said.

Disclosure information for study authors is available in the original study publication. The study was funded by the Drug and Medical Devices Governance Area in Emilia-Romagna in Bologna, IRCCS Institute of Neurological Sciences of Bologna, and the Italian Ministry of Health. Knopman reported being a DSMB for Roche for an investigational agent, trontinemab.

https://www.medscape.com/viewarticle/no-clinical-benefit-antiamyloids-alzheimers-review-concludes-2026a1000c32

Rise of Early Onset Diabetes a Looming Crisis

 When Sheela N. Magge, MD, began her pediatric endocrinology fellowship at Children’s Hospital of Philadelphia in 2001, she began witnessing an extraordinary phenomenon unfolding in the hospital’s pediatric endocrinology ward. 

Youngsters coming in with symptoms of diabetic ketoacidosis were leaving with diagnoses of type 2 diabetes mellitus, long considered an adult disease. 

“It was remarkable,” said Magge, Lawson Wilkins chair of pediatric endocrinology, and director of the Division of Pediatric Endocrinology, Johns Hopkins School of Medicine, Baltimore.

That once-remarkable diagnosis has become more commonplace in pediatric specialists’ offices. But young people don’t stay young forever. And diabetes just doesn’t disappear. Plus, experts said, there are not enough trained pediatric endocrinologists, or enough obesity-trained professionals either, to handle what’s coming. 

Eventually the day will come when these patients will seek care from providers who treat adults. And a large concern among pediatric specialists is that primary care physicians (PCPs), the medical world’s version of baseball’s shortstop, will not be prepared to fully grasp what they are up against, namely a disease that is far more advanced, far more complicated, and far more deadly — from a premature mortality vantage point — than the adult version. 

Numerous studies over the years, like the years-long TODAY and SEARCH trials, have proven these statements true; studies to understand why they are true are underway. 

At the age of diagnosis, on average around 15 years old, 20% already have one complication, said Stephanie Chung, MBBS, an investigator with the National Institute of Diabetes and Digestive and Kidney Diseases. Ten years later, more than 50% of these patients do, and 15 years later 80% have at least one diabetes-related complication, including hypertension and early diabetic kidney disease. This contrasts with adults with diabetes; 25% develop diabetic kidney disease after 10 years. 

An entire generation of these children could be lost to follow-up when they reach adulthood, said Magge. 

Even endocrinologists who treat adults might not be well versed in pediatric diabetes. “When the [landmark] TODAY long-term outcomes were published in 2021, an endocrinologist I know called me and said, ‘Oh my God.’” 

These adult patients generally have better outcomes if they remain in pediatric care. 

An in-tandem consequence of the 1990s surge in obesity, youth-onset diabetes (under 18) is projected to rise in this country to 220,000 cases by 2060. The global incidence of those diagnosed with type 2 before age 25 continues its trend upward: 183.4 in 2019 (per 100,000) up from 117.2 in 1990. 

A meta-analysis of 48 studies, published through 2021, showed that childhood prediabetes increased to 10.66% from 0.93%. During prediabetes, mild hyperglycemia could increase unforetold cardiovascular issues. (Studies often distinguish youth-onset as diagnosis under 18 and early or young-onset to be under 40 years old.)

“It is an epidemic,” said Jennifer Sherr, MD, professor of pediatrics and medical director of the pediatric diabetes program at Yale University School of Medicine, New Haven, Connecticut. When asked to explain what makes it an epidemic — uncontrolled glycemic levels, more youngsters being diagnosed — she replied with “All of the above.” 

A Different Kind of Disease 

This disease, which some say should be treated as a distinct type of diabetes because of its distinct pathophysiology in the young, has complications that require respect. It is affecting tweens and teens, youngsters who are often under stress, especially those who live in less than desirable socioeconomic situations — and many, many do. 

And biologically, puberty is a time in which all teens are insulin resistant due to a spike in growth-hormone and insulin-like growth factor; these two increase insulin resistance. 

Adherence, to no one’s surprise, does not come easy, and it’s a deep concern. In adults with diabetes, the annual rate of beta cell function decline ranges between 2% and 5%; in youngsters, it’s about 25%. 

Youth-onset diabetes assaults young kidneys, the cardiovascular and endocrine systems. A child diagnosed in middle school could be dead by 40; a 2003, real-world study showed that adults with early-onset had twice the hazard — 7.9 vs 3.8 — of any macrovascular complication vs controls. The most common complication was a myocardial infarction; the hazard rate was 14-fold higher. 

The phrase “aggressive treatment” was repeated by all interviewed.

Obesity, insulin resistance, prediabetes, and diabetes cause “states of chronic inflammation, leading to a significant increase in risk for premature micro and macrovascular complications,” said Timothy Gilbert, MD, director of the Pennington Biomedical Outpatient Endocrine and Diabetes Clinic in Baton Rouge, Louisiana. These patients have an inflamed endovascular state, leading to more plaque deposition, more arterial thickness, and an increased potential for embolic events, he said. 

Genetics Play a Role 

Youth-onset also has a significant genetic component. Many of those interviewed described exam-room scenes in which the child was asked if anyone in the family also had diabetes, and the accompanying parent or relative would chime in, “I do.” And sometimes, that person was diagnosed in their 20s or 30s.

“With that genetic predisposition and the really high BMIs that we’re seeing, it’s certainly creeping earlier and earlier,” said psychologist Amanda Staiano, PhD, director of the Pediatric Obesity and Health Behavior Laboratory, Pennington Biomedical Research Center, Baton Rouge, discussing the ages of participants in her trials. 

“The window to intervene meaningfully is narrow, and every month of suboptimal glycemic, blood pressure, and lipid control accelerates the path toward complications,” said Petter Bjornstad, MD, Raisbeck endowed chair of diabetes research; executive director of the UW Medicine Diabetes Institute; principal investigator at the Center for Clinical and Translational Research, Seattle Children’s Research Institute.

Treating Youth-Onset Diabetes 

As Gilbert put it, “We are not grabbing for metformin first anymore.”

Until the last few years, pediatric clinicians only had metformin and insulin to treat young patients. The FDA has recently approved other medications for youth-onset, namely, the sodium-glucose cotransporter 2 inhibitors — including dapagliflozin, empagliflozin, and empagliflozin/metformin — and GLP-1s, namely dulaglutide, liraglutide, semaglutide, and tirzepatide. 

So far, there is no firm guidance for treatment of hypertension and hyperlipidemia in adolescents with type 2 diabetes. Without the data, said Gilbert, “I sort of treat them like an adult from a medical standpoint,” adding that the patients are typically of adult size, so the strategy is to treat the patients as if they have an adult disease.

These additions are welcome, as metformin doesn’t work well in most kids. Metformin was designed to improve blood glucose levels by decreasing glucose production in the liver and increasing insulin sensitivity. But these youngsters have high insulin resistance levels and rapidly declining insulin secretion, said Chung. “Metformin can’t rescue the decline in pancreatic function and b-cell failure, because they continue to be under stress,” she said.

And because they’re kids, they could ignore how they are feeling, letting time pass before seeking treatment. “So long term exposure, that lingering hyperglycemia is always present, causing end-stage organ damage,” Chung added.

Gilbert would like to see his patients use continuous glucose monitors (CGMs) earlier in the treatment course. 

“The ADA [American Diabetes Association] is recommending CGM for everyone. We are still in the clinical practice world, bound by insurance coverage. We can want it, but a lot of insurances are still requiring use of a single shot of insulin/day to get CGM.”

Chung was hopeful. “The landscape should change as we get more GLP-1ras approved that can target weight loss and improve beta cell function.”

PCPs Get Advice 

The literature is limited regarding the transitioning of youth with type 2 to adult care, Chung et al reported last year. That said, all interviewed gladly gave PCPs advice on helping their adult patients with youth-onset type 2 diabetes.

First, the numbers: What’s considered low in an adult isn’t necessarily low in youth-onset. Magge said a young adult with type 2 whose A1c is low, like 5.8 kind of low, should stay on metformin. 

“Parents look at me. ‘You are prescribing 1000 mg twice a day of metformin when I am on less?’” Yes, she said. “We want children to have long and healthy lives.”

Also ask about acanthosis nigricans— a sign of insulin resistance, nocturia, frequent infections, including yeast — because these are signs of hyperglycemia, Chung said.

And screen, screen, screen: kidneys, blood pressure, dyslipidemia. “Make sure they are vigilant about timing of screening. Don’t feel that they are not at high risk,” Magge said. The ADA, she said, recommends A1c testing every 3 months.

Sherr emphasized relationships. Even if a patient has an endocrinologist, that specialist and the PCP have to tell the same story: They can be reinforcing the importance of glucose levels and exercise. Relaying this information should not take long during the exam, she said. And bring in family members; significant others can be very helpful diabetes management enforcers. All interviewed stressed this point.

Staiano discussed a different reality. 

“We need PCPs to do this medical management for early prevention and medical management, so the more complicated cases can go to the specialists.” 

Of course, there aren’t enough PCPs either.

“I don’t envy the PCPs,” said Magge. “It’s a lot to keep track of.”

Sherr’s institution has received research support from Abbott Diabetes, Dexcom, Breakthrough T1D, Insulet, Medtronic, NIH, Provention Bio, and the T1D Exchange; she consults for Abbott Diabetes, Insulet, Medscape, Medtronic Diabetes, Vertex, and Ypsomed; and served on an advisory board for Cecelia Health, Insulet, MannKind, Medtronic Diabetes, Sequel Med Tech, StartUp Health’s T1D Moonshot, and Vertex. Gilbert is a speaker/consultant for Novo Nordisk, Dexcom, and MiniMed. Magge, Chung, Bjornstad, and Staiano reported no disclosures.

https://www.medscape.com/viewarticle/rise-early-onset-diabetes-looming-crisis-2026a1000c57

US grants oil SPR loans to nine companies

 The United States Department of Energy (DoE) announced on Friday that it will loan 26 million barrels of oil from the country's Strategic Petroleum Reserves (SPR) to American subsidiaries of nine major energy companies.

According to the department's official statements, the loans were granted to US divisions of BP PLC, Delek US Holdings Inc., Energy Transfer Crude Marketing, Exxon Mobil Corporation, Macquarie Commodities Trading, Marathon Petroleum Corporation, Shell PLC, Trafigura Group Pte. Ltd., and Vitol.

The DoE noted that the loans "will be returned with additional premium barrels by next year—supporting energy security and delivering value for the American people at no cost to taxpayers." It added that the selected companies "can begin scheduling deliveries immediately."

https://breakingthenews.net/Article/US-grants-oil-SPR-loans-to-nine-companies/66095845

'Iran: New Hormuz regime requires tolls'

 Iranian Parliament's National Security Commission Ebrahim Azizi said on Friday that vessels must comply with a new maritime regime in the Strait of Hormuz, necessitating authorization and toll payments.

"The time has come to comply with the new Maritime Regime of the Strait of Hormuz," Azizi stated on X. He added that the rules are "determined by Iran, not by social media posts! Under this new system, only commercial vessels with authorization from the IRGC [Islamic Revolutionary Guard Corps] Navy are permitted to navigate through designated routes after paying the required tolls."

"If the U.S. attempts to create any disturbance for Iranian ships, this situation can easily be changed," he concluded. Earlier, Iran said that the key waterway's reopening will serve as a test of the United States' "firm commitments." Meanwhile, US President Donald Trump said that the strait will not be closed again, claiming that Iran has agreed to "everything."

https://breakingthenews.net/Article/Iran:-New-Hormuz-regime-requires-tolls/66095807

Critical Metals Shares Surge After Expanding Rare Earth Mining Position In Greenland

 Critical Metals Corp. shares have surged as much as 45% in trading today after the company significantly expanded its position in Greenland’s Tanbreez rare earth project, tightening its grip on a resource it sees as central to a US-friendly supply chain, according to Bloomberg.

It marks the biggest intraday gain in half a year and lifting the company’s valuation to roughly $1.7 billion.

According to documents reviewed by Bloomberg, the firm raised its ownership to 92.5% by purchasing the remaining 50.5% stake it previously didn’t control from Rimbal Pty Ltd. The company confirmed the transaction in a statement released Friday.

With this deal, Critical Metals now holds a dominant share of Tanbreez, a deposit rich in rare earth elements such as terbium and dysprosium—materials essential for electronics and defense systems. The company describes Tanbreez as one of the largest known rare earth resources globally.

“We believe this important catalyst and hurdle now achieved helps to accelerate the approval by the Greenland government for permitting to commence mining," said Analyst Tim Moore from Clear Street. He has a $20 price target on the name and sees the increased stake as  "positive with funding matching estimates and control change being approved after previous delays", per Bloomberg. 

The acquisition comes amid a broader push by the US and its partners to lock in supplies of critical minerals and lessen dependence on China, which still leads the world in rare earth processing. Greenland, with its vast untapped reserves, has become an increasingly strategic location—though projects there remain costly and face regulatory hurdles.

Over the past year, Greenland has drawn growing attention from Washington, with renewed political and commercial interest reflecting its rising importance in global resource competition.

The island is no longer just a remote outpost—it’s becoming a focal point in the evolving economic and geopolitical relationship between Greenland and the United States.

https://www.zerohedge.com/markets/critical-metals-shares-surge-40-after-expanding-rare-earth-mining-position-greenland

"Overwhelming Puke-Stream": It's All Going To Come Out Now...

 by James Howard Kunstler,

Showdown

“Everything that’s wrong is staring us right in the face, and half this country simply will not join us in fighting and fixing it. It’s infuriating and depressing and maddening.”

- James Woods on X

The closer this Iran war comes to a favorable resolution, the more garishly negative the puling Lefty-left gets, wishing fervently for the enemy to prevail. Why? Because the Lefty-left is also an enemy of our country. They want the operation to fail so they can reclaim power and resume wrecking and looting the USA.

By the way, what exactly would a favorable outcome of this war look like?

An Iran that doesn’t threaten nuclear jihad and doesn’t sponsor endless terror operations here, there, and everywhere. It looks like we are going to get to that. Iran’s choice is how deep do they want to take their own economic collapse before capitulating? If they’ll just stop now, they’ll still keep the lights on. They can be a normal, modern, developed nation without a death wish.

Anyway, the paradigm Iran was operating in as a rogue state is dead, especially the malign influence of Britain’s banking and MI6 intel matrix. Britain, proven by its actions to be not a friend of America. . . Britain, a wretched little has-been island empire with bad teeth, overrun by wrathful Islamists, and, alas, soon to be a caliphate.

President Donald Trump has rearranged the geopolitical landscape with startling speed and efficacy. Much of Europe, it turns out, are not our friends, either. They would not let us use the NATO bases we pay for to conduct air operations over Iran. Hence, NATO is four dead letters. They can go dangle while they figure out how to live without oil, possibly go back to their centuries-long condition as a nonstop slaughterhouse, besetting each other with stupid, age-old feuds. Not our problem anymore.

China?

Their Belt-and-Road isn’t what it was just six months ago. Mr. Trump has kicked them out of South America. Their oil supply is suddenly sketchy. Notice, they didn’t lend a hand helping to clear the Strait of Hormuz. Turned out that the radars and air defenses they gifted Iran didn’t work too well. Uncle Xi Pooh Bear will have to re-think situation.

Mr. Trump says he might travel to Pakistan this weekend if there are papers to sign with Iran.

Israel and Lebanon announced a ten-day truce to sort out where things stand. Both of them want Hezbollah expelled for good. Anyway, Hezbollah can no longer enjoy financial support from Iran, meaning no more munitions or salaries for Hezbollah warriors, meaning Hezbollah is out of business — a major regional irritant neutralized. Can you dare to imagine a peaceable Middle East?

So, things have changed-up greatly in this long-volatile corner of the world, and that will leave Mr. Trump freer to attend to the discord and animus at home, namely the psychopathic Democratic Party’s non-stop demolition of political norms, with assistance from the bureaucratic Deep State and the NGO underworld.

Just at hand this week, we have Director of National Intelligence Tulsi Gabbard sending criminal referrals to the DOJ on two key players (both liars) in Trump Impeachment No. 1: former Intel Inspector General Michael Atkinson and CIA agent “whistleblower” Eric Ciaramella — whose name the news media still fears to speak.

That impeachment, over the so-called “Ukraine phone call,” was from start to finish a complete fake, a criminal conspiracy. It involves a much larger cast-of-characters including then House Intel Committee Chair (now senator) Adam Schiff, then Secretary of State Mike Pompeo, CIA Director Gina Haspel, Chief Justice John Roberts, and virtually the whole Kiev US embassy staff at the time. Everybody involved was lying about one thing or another. The case is on Acting AG Todd Blanche’s desk now. Do you suppose it can just sit there?

It’s rumored that in the weeks ahead, Mr. Trump is fixing to conduct a declassification orgy of evidence unearthed by DNI Gabbard in the serial seditions run by US color revolutionists over the past decade. The presidential declass will obviate the usual tedious process of extracting declass permissions from every agency silo with a stake in the documents — meaning the evidence will go straight to US attorneys, including Jason Reding Quiñones, the United States Attorney for the Southern District of Florida, now running a grand jury out of Fort Pierce on the RussiaGate hoax.

Many of the players in that treasonous episode were involved in subsequent crimes against the nation: the 2020 election fraud; the Jan. 6 fed-provoked “insurrection” at the US Capitol; the fake House committee set up to pretend to investigate it; the Mar-a-Lago Raid; the multiple Trump prosecutions of 2024, the censorship campaign; and the manifold perfidious turpitudes of the “Joe Biden” administration, including the massive invasion of illegal immigrants.

It’s all going to come out now in one overwhelming puke-stream channeled into actual prosecutions. Only question is: will the massive revelation of truth prompt the millions of successfully brainwashed Americans to finally get their minds right over what has been perpetrated on our country?

https://www.zerohedge.com/political/overwhelming-puke-stream-its-all-going-come-out-now